Cwm LLC Buys 29,483 Shares of Cerus Corporation $CERS

Cwm LLC grew its stake in Cerus Corporation (NASDAQ:CERS) by 36.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 110,654 shares of the biotechnology company’s stock after acquiring an additional 29,483 shares during the quarter. Cwm LLC owned 0.06% of Cerus worth $156,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Acadian Asset Management LLC raised its stake in shares of Cerus by 112.5% in the first quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company’s stock worth $2,637,000 after buying an additional 1,005,079 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Cerus by 218.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 50,972 shares of the biotechnology company’s stock worth $71,000 after buying an additional 34,968 shares during the period. Rhumbline Advisers raised its stake in shares of Cerus by 5.5% in the first quarter. Rhumbline Advisers now owns 251,907 shares of the biotechnology company’s stock worth $350,000 after buying an additional 13,112 shares during the period. R Squared Ltd raised its stake in Cerus by 106.7% during the 1st quarter. R Squared Ltd now owns 38,655 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 19,955 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Cerus by 6.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company’s stock worth $2,466,000 after acquiring an additional 107,771 shares during the period. Institutional investors own 78.37% of the company’s stock.

Cerus Stock Performance

Shares of NASDAQ CERS opened at $1.40 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.35 and a current ratio of 2.00. The company has a market cap of $268.38 million, a P/E ratio of -14.00 and a beta of 1.70. The firm’s fifty day moving average is $1.44 and its two-hundred day moving average is $1.38. Cerus Corporation has a 52-week low of $1.12 and a 52-week high of $2.24.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The business had revenue of $60.10 million during the quarter, compared to the consensus estimate of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cerus in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cerus presently has a consensus rating of “Hold” and an average target price of $4.00.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.